UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): May 22, 2026

 

IMMIX BIOPHARMA, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware		001-41159		45-4869378
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

 

11400 West Olympic Blvd., Suite 200

Los Angeles, CA 90064

(Address of principal executive offices)

 

(310) 651-8041

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

 

Securities registered pursuant to Section 12(b)of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value of $0.0001 per share		IMMX		The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On May 22, 2026, at the 2026 Annual Meeting of stockholders (the “Annual Meeting”) of Immix Biopharma, Inc. (the “Company”), the Company’s stockholders voted on the following two (2) proposals and votes were cast as described below. These matters are described in more detail in the Definitive Proxy Statement on Schedule 14A filed by the Company with the Securities and Exchange Commission on April 6, 2026.

 

The final results of voting on each proposal presented at the Annual Meeting are set forth below.

 

1.

Proposal 1 — Election of Directors Proposal   The stockholders elected each of the individuals listed below to serve as a director of the Company until the next annual meeting of stockholders and until such director’s successor is duly elected and qualified. The results of the voting for this proposal were as follows:

 

		For				Withheld				Broker Non-Votes
Ilya Rachman			35,738,887				121,893				6,445,684
Gabriel Morris			34,353,302				1,507,479				6,445,683
Jason Hsu			35,844,812				15,969				6,445,683
Magda Marquet			35,731,188				129,592				6,445,684
Helen C. Adams			35,677,258				183,522				6,445,684
Carey Ng			35,840,860				19,921				6,445,683
Jane Buchan			35,731,346				129,434				6,445,684
Yekaterina Chudnovsky			35,749,420				111,360				6,445,684
Nancy Chang			35,744,455				116,325				6,445,684

 

2.

Proposal No. 2 — Ratification of Auditors Proposal   The stockholders ratified the appointment of Crowe LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The results of the voting for this proposal were as follows:

 

For		Against				Abstentions				Broker Non-Votes
42,276,496			11,526				18,442				—

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	Immix Biopharma, Inc.
Dated: May 29, 2026	/s/ Ilya Rachman
	Ilya Rachman, M.D., Ph.D.
	Chief Executive Officer